Comparison · NCT04553068-e4cf9ab9
EVO100 Gel vs Placebo Gel: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. EVO100 Gel vs Placebo Gel: Percentage of Study Successes in the EVO100 and Placebo Treatment Groups. Trial comparisons, record NCT04553068-e4cf9ab9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04553068-e4cf9ab9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.755 | 0.726 | 0.782 | wilson | |
| Risk in group 2 | 0.762 | 0.734 | 0.789 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00736 | -0.0467 | 0.032 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.99 | 0.94 | 1.04 | log | |
| Odds ratio, group 1 over group 2 | 0.961 | 0.775 | 1.19 | log | |
| Number needed to treat, for one fewer participant with the outcome on EVO100 Gel than on Placebo Gel | 136 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | EVO100 Gel | EVO100 vaginal gel, 5 g~EVO100: EVO100 vaginal gel | 684 | 906 | OG000 |
| Group 2 | Placebo Gel | Placebo vaginal gel, 5 g~Placebo: Placebo vaginal gel | 696 | 913 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Percentage of Study Successes in the EVO100 and Placebo Treatment Groups
- Description
Percentage of subjects who are defined study successes among the intervention groups with success defined as subjects completing the trial to Visit 5 without any CT or GC infection and no usage of prohibited antibiotics during the study.
- Time frame
- 16 weeks
- Population
- mITT
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
- NCT number
- NCT04553068
- Phases
- PHASE3
- Conditions
- Sexually Transmitted Diseases, Gonorrhea, Chlamydia
- Interventions
- EVO100, Placebo
- Lead sponsor
- Evofem Inc.
- Results first posted
- 2024-01-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04553068?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04553068-e4cf9ab9